A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
Open Access
- 12 October 2012
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (5) , R217
Abstract
Introduction: Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness. Prior trials have demonstrated the efficacy of pregabalin for the relief of fibromyalgia symptoms, and it is approved for the treatment of fibromyalgia in the United States. However, prior to this study, there has not been a large-scale efficacy trial in patients with fibromyalgia in Japan. Methods: This randomized, double-blind, multicenter, placebo-controlled trial was conducted at 44 centers in Japan to assess the efficacy and safety of pregabalin for the symptomatic relief of pain in fibromyalgia patients. Patients aged ≥18 years who had met the criteria for fibromyalgia were randomized to receive either pregabalin, starting at 150 mg/day and increasing to a maintenance dose of 300 or 450 mg/day, or placebo, for 15 weeks. The primary efficacy endpoint was mean pain score at final assessment. Secondary endpoints included Patient Global Impression of Change (PGIC) together with measures of sleep, physical functioning and quality of life. Results: A total of 498 patients (89% female) were randomized to receive either pregabalin (n = 250) or placebo (n = 248). Pregabalin significantly reduced mean pain score at final assessment (difference in mean change from baseline, compared with placebo -0.44; P = 0.0046) and at every week during the study (P P = 0.0078); pain visual analog scale (difference in mean change from baseline, compared with placebo -6.19; P = 0.0013); Fibromyalgia Impact Questionnaire total score (-3.33; P = 0.0144); and quality of sleep score (-0.73; P <0.0001). Treatment was generally well tolerated, with somnolence and dizziness the most frequently reported adverse events. Conclusions: This trial demonstrated that pregabalin, at doses of up to 450 mg/day, was effective for the symptomatic relief of pain in Japanese patients with fibromyalgia. Pregabalin also improved measures of sleep and functioning and was well tolerated. These data indicate that pregabalin is an effective treatment option for the relief of pain and sleep problems in Japanese patients with fibromyalgia. Trial Registration: ClinicalTrials.gov: NCT00830167Keywords
This publication has 32 references indexed in Scilit:
- Research platform for fibromyalgia in JapanArthritis Research & Therapy, 2012
- The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom SeverityArthritis Care & Research, 2010
- Fibromyalgia Syndrome Module at OMERACT 9: Domain ConstructThe Journal of Rheumatology, 2009
- Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgiaHealth and Quality of Life Outcomes, 2009
- Sleep disturbances in fibromyalgia syndrome: Relationship to pain and depressionArthritis Care & Research, 2008
- Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient delphi exercisesArthritis Care & Research, 2008
- Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalinProceedings of the National Academy of Sciences, 2006
- The prevalence and characteristics of fibromyalgia in the general populationArthritis & Rheumatism, 1995
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- The american college of rheumatology 1990 criteria for the classification of fibromyalgiaArthritis & Rheumatism, 1990